Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Drops Acoalan’s Preeclampsia Program after PIII Miss
Kyowa Kirin said on November 1 that it will discontinue the development of its blood preparation Acoalan (antithrombin gamma) for the treatment of preeclampsia following a PIII clinical trial failure. The company had reported in September that the drug, also…
To read the full story
Related Article
- Acoalan Misses Mark in PIII Preeclampsia Trial: Kyowa Kirin
September 29, 2023
- Acoalan’s PIII Trial for Preeclampsia Due to Complete in July: Kyowa Kirin
January 23, 2023
- Kyowa Kirin Launches Japan PIII for Acoalan in Preeclampsia
November 21, 2019
BUSINESS
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…